TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)
Brief Summary: The purpose of this study was to determine whether ruxolitinib added to capecitabine is effective in improving the overall survival of patients with metastatic pancreatic cancer.


Options:
A: Arm Label: Masitinib & gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: Masitinib, Drug: Gemcitabine | Arm Label: Placebo & gemcitabine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Gemcitabine | Intervention Type: DRUG; Name: Masitinib; Assigned to Arm(s): Masitinib & gemcitabine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo & gemcitabine | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Masitinib & gemcitabine, Placebo & gemcitabine
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine+erlotinib | Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine+erlotinib+capecitabine | Intervention Type: DRUG; Name: Gemcitabine+erlotinib; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Gemcitabine+erlotinib+capecitabine; Assigned to Arm(s): Experimental
C: Arm Label: Capecitabine and ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine, Drug: Ruxolitinib | Arm Label: Capecitabine and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Placebo | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Capecitabine and placebo, Capecitabine and ruxolitinib | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Capecitabine and ruxolitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Capecitabine and placebo
D: Arm Label: Placebo + gemcitabine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: gemcitabine | Arm Label: AMG 479 12 mg/kg dose + gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: AMG 479, Drug: gemcitabine | Arm Label: AMG 479 20 mg/kg + gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: AMG 479, Drug: gemcitabine | Intervention Type: DRUG; Name: AMG 479; Assigned to Arm(s): AMG 479 12 mg/kg dose + gemcitabine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + gemcitabine | Intervention Type: DRUG; Name: AMG 479; Assigned to Arm(s): AMG 479 20 mg/kg + gemcitabine | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): AMG 479 12 mg/kg dose + gemcitabine, AMG 479 20 mg/kg + gemcitabine, Placebo + gemcitabine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supplemental Oxygen in Catheterized Coronary Emergency Reperfusion
Brief Summary: The aim of SOCCER is to evaluate the effects of treatment with supplemental O2 before and during acute balloon angioplasty (PCI) for patients with ST-elevation myocardial infarction (STEMI). One hundred STEMI patients are randomized in the ambulance to either standard O2 treatment (10 l/min) or no supplemental O2, to be given until the end of the acute PCI. Cardiac magnetic resonance imaging and echocardiography during the hospital stay is used to assess infarct size and myocardial performance. All patients are followed for 6 months. At 6 months, perceived health and NT-proBNP are recorded for all patients, and an additional echocardiography is performed. The primary endpoint is the fraction of myocardium saved with the acute PCI. The secondary endpoints include the pain difference between inclusion time and start of PCI and myocardial performance on echocardiography.


Options:
A: Arm Label: Lower SpO2 Target; Type: ACTIVE_COMPARATOR; Interventions: Other: Lower SpO2 Target | Arm Label: Intermediate SpO2 Target; Type: ACTIVE_COMPARATOR; Interventions: Other: Intermediate SpO2 Target | Arm Label: Higher SpO2 Target; Type: ACTIVE_COMPARATOR; Interventions: Other: Higher SpO2 Target | Intervention Type: OTHER; Name: Lower SpO2 Target; Assigned to Arm(s): Lower SpO2 Target | Intervention Type: OTHER; Name: Intermediate SpO2 Target; Assigned to Arm(s): Intermediate SpO2 Target | Intervention Type: OTHER; Name: Higher SpO2 Target; Assigned to Arm(s): Higher SpO2 Target
B: Arm Label: Nasal oxygen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nasal oxygen | Arm Label: Nasal Air; Type: PLACEBO_COMPARATOR; Interventions: Drug: Regular nasal air | Intervention Type: DRUG; Name: Nasal oxygen; Assigned to Arm(s): Nasal oxygen | Intervention Type: DRUG; Name: Regular nasal air; Assigned to Arm(s): Nasal Air
C: Arm Label: 10 L O2/min; Type: EXPERIMENTAL; Interventions: Drug: Oxygen | Arm Label: Room air; Type: SHAM_COMPARATOR; Interventions: Device: Room air | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): 10 L O2/min | Intervention Type: DEVICE; Name: Room air; Assigned to Arm(s): Room air
D: Arm Label: No oxygen; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Oxygen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): Oxygen

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet Composition and Genetics: Effects on Weight, Inflammation and Biomarkers
Brief Summary: The purpose of the MENU Study is to examine whether there is a differential weight loss response to different dietary macronutrient composition (higher carbohydrate and lower fat versus lower carbohydrate and higher monounsaturated fat \[MUFA\] or lower carbohydrate and walnut-rich higher fat diets) in a weight loss intervention in healthy obese women, depending on insulin resistance status. Blood samples will be collected to enable analysis of potential mechanisms and differential response across subgroups.


Options:
A: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A
B: Arm Label: Lower fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Lower carbohydrate diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Walnut-rich diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Intervention Type: BEHAVIORAL; Name: Weight loss; Assigned to Arm(s): Lower carbohydrate diet, Lower fat diet, Walnut-rich diet
C: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Drug: Fish oil | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fish oil; Assigned to Arm(s): Fish oil
D: Arm Label: Vitamin D3 + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3, Dietary Supplement: fish oil | Arm Label: Vitamin D3 + fish oil placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3, Dietary Supplement: Fish oil placebo | Arm Label: Vitamin D3 placebo + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: fish oil, Dietary Supplement: Vitamin D3 placebo | Arm Label: Vitamin D3 placebo + fish oil placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 placebo, Dietary Supplement: Fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 + fish oil, Vitamin D3 + fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: fish oil; Assigned to Arm(s): Vitamin D3 + fish oil, Vitamin D3 placebo + fish oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 placebo; Assigned to Arm(s): Vitamin D3 placebo + fish oil, Vitamin D3 placebo + fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish oil placebo; Assigned to Arm(s): Vitamin D3 + fish oil placebo, Vitamin D3 placebo + fish oil placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet Composition and Genetics: Effects on Weight, Inflammation and Biomarkers
Brief Summary: The purpose of the MENU Study is to examine whether there is a differential weight loss response to different dietary macronutrient composition (higher carbohydrate and lower fat versus lower carbohydrate and higher monounsaturated fat \[MUFA\] or lower carbohydrate and walnut-rich higher fat diets) in a weight loss intervention in healthy obese women, depending on insulin resistance status. Blood samples will be collected to enable analysis of potential mechanisms and differential response across subgroups.


Options:
A: Arm Label: Safflower oil; Type: EXPERIMENTAL; Interventions: Other: Safflower oil | Arm Label: Control group (no diet instruction); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Safflower oil; Assigned to Arm(s): Safflower oil
B: Intervention Type: PROCEDURE; Name: Supplementation with fish oil versus placebo; Assigned to Arm(s): N/A
C: Arm Label: Lower fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Lower carbohydrate diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Walnut-rich diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Intervention Type: BEHAVIORAL; Name: Weight loss; Assigned to Arm(s): Lower carbohydrate diet, Lower fat diet, Walnut-rich diet
D: Arm Label: Insulin glargine + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: omega-3 polyunsaturated fatty acids (PUFA), Device: reusable pen device for insulin injection | Arm Label: Insulin glargine + placebo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: placebo, Device: reusable pen device for insulin injection | Arm Label: Standard care + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: omega-3 polyunsaturated fatty acids (PUFA) | Arm Label: Standard care + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: insulin glargine (HOE901); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo | Intervention Type: DRUG; Name: omega-3 polyunsaturated fatty acids (PUFA); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Standard care + omega-3 polyunsaturated fatty acids | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Insulin glargine + placebo, Standard care + placebo | Intervention Type: DEVICE; Name: reusable pen device for insulin injection; Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet Composition and Genetics: Effects on Weight, Inflammation and Biomarkers
Brief Summary: The purpose of the MENU Study is to examine whether there is a differential weight loss response to different dietary macronutrient composition (higher carbohydrate and lower fat versus lower carbohydrate and higher monounsaturated fat \[MUFA\] or lower carbohydrate and walnut-rich higher fat diets) in a weight loss intervention in healthy obese women, depending on insulin resistance status. Blood samples will be collected to enable analysis of potential mechanisms and differential response across subgroups.


Options:
A: Arm Label: Lower fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Lower carbohydrate diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Walnut-rich diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Intervention Type: BEHAVIORAL; Name: Weight loss; Assigned to Arm(s): Lower carbohydrate diet, Lower fat diet, Walnut-rich diet
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsule | Arm Label: EPA-E 1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Arm Label: EPA-E 2700 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 1800 mg/day | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 2700 mg/day
C: Arm Label: Pikasol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pikasol | Arm Label: Corn oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Corn oil | Intervention Type: DRUG; Name: Pikasol; Assigned to Arm(s): Pikasol | Intervention Type: OTHER; Name: Corn oil; Assigned to Arm(s): Corn oil
D: Arm Label: EPA + DHA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: EPA + DHA plus ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: margarine spread | Intervention Type: DIETARY_SUPPLEMENT; Name: margarine spread; Assigned to Arm(s): ALA, EPA + DHA, EPA + DHA plus ALA, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet Composition and Genetics: Effects on Weight, Inflammation and Biomarkers
Brief Summary: The purpose of the MENU Study is to examine whether there is a differential weight loss response to different dietary macronutrient composition (higher carbohydrate and lower fat versus lower carbohydrate and higher monounsaturated fat \[MUFA\] or lower carbohydrate and walnut-rich higher fat diets) in a weight loss intervention in healthy obese women, depending on insulin resistance status. Blood samples will be collected to enable analysis of potential mechanisms and differential response across subgroups.


Options:
A: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Drug: Fish oil | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fish oil; Assigned to Arm(s): Fish oil
B: Arm Label: Lower fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Lower carbohydrate diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Walnut-rich diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Intervention Type: BEHAVIORAL; Name: Weight loss; Assigned to Arm(s): Lower carbohydrate diet, Lower fat diet, Walnut-rich diet
C: Arm Label: EPA + DHA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: EPA + DHA plus ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: margarine spread | Intervention Type: DIETARY_SUPPLEMENT; Name: margarine spread; Assigned to Arm(s): ALA, EPA + DHA, EPA + DHA plus ALA, Placebo
D: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet Composition and Genetics: Effects on Weight, Inflammation and Biomarkers
Brief Summary: The purpose of the MENU Study is to examine whether there is a differential weight loss response to different dietary macronutrient composition (higher carbohydrate and lower fat versus lower carbohydrate and higher monounsaturated fat \[MUFA\] or lower carbohydrate and walnut-rich higher fat diets) in a weight loss intervention in healthy obese women, depending on insulin resistance status. Blood samples will be collected to enable analysis of potential mechanisms and differential response across subgroups.


Options:
A: Arm Label: AMR101; Type: EXPERIMENTAL; Interventions: Drug: AMR101, Drug: Statin therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Statin therapy | Intervention Type: DRUG; Name: AMR101; Assigned to Arm(s): AMR101 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): AMR101, Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Multi-nutrient supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multi-nutrient supplement | Arm Label: Placebo + Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation, Other: Placebo | Arm Label: Multi-nutrient + Behavioral Activation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multi-nutrient supplement, Behavioral: Behavioral Activation | Intervention Type: DIETARY_SUPPLEMENT; Name: Multi-nutrient supplement; Assigned to Arm(s): Multi-nutrient + Behavioral Activation, Multi-nutrient supplement | Intervention Type: BEHAVIORAL; Name: Behavioral Activation; Assigned to Arm(s): Multi-nutrient + Behavioral Activation, Placebo + Behavioral Activation | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo, Placebo + Behavioral Activation
C: Arm Label: Lower fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Lower carbohydrate diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Walnut-rich diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Intervention Type: BEHAVIORAL; Name: Weight loss; Assigned to Arm(s): Lower carbohydrate diet, Lower fat diet, Walnut-rich diet
D: Arm Label: Omega-3 supplements; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega-3 supplements; Assigned to Arm(s): Omega-3 supplements | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Baby Observational and Nutritional Study (BONUS)
Brief Summary: Cystic fibrosis (CF) is a life-shortening disease that causes breathing and digestive problems, but can now be diagnosed at the time of birth. Lung function is very hard to measure in infants, but growth is not. In this study the investigators aim to define growth in infants with CF in the first year of life with research quality precision and to understand factors that interfere with good growth.

Pancreatic enzyme replacement therapy (PERT) will be also be studied in a subgroup of infants. Two different doses of PERT will be evaluated for improving fat and nitrogen absorption in infants with CF.


Options:
A: Arm Label: Patients with CF; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Arm Label: Age-matched healthy controls; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Intervention Type: DIAGNOSTIC_TEST; Name: Questionnaire Patient Reported Outcome Measure (PROM); Assigned to Arm(s): Age-matched healthy controls, Patients with CF
B: Arm Label: Cystic Fibrosis in 1st 3 months of life; Type: N/A; Interventions: N/A
C: Arm Label: Liprotamase; Type: EXPERIMENTAL; Interventions: Drug: Liprotamase | Arm Label: porcine (pig) PERT; Type: ACTIVE_COMPARATOR; Interventions: Drug: porcine (pig) PERT | Intervention Type: DRUG; Name: Liprotamase; Assigned to Arm(s): Liprotamase | Intervention Type: DRUG; Name: porcine (pig) PERT; Assigned to Arm(s): porcine (pig) PERT
D: Arm Label: Burlulipase; Type: EXPERIMENTAL; Interventions: Drug: Burlulipase | Arm Label: Placebo (Caramel in sterile water); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (Caramel in sterile water) | Intervention Type: DRUG; Name: Burlulipase; Assigned to Arm(s): Burlulipase | Intervention Type: DRUG; Name: Placebo (Caramel in sterile water); Assigned to Arm(s): Placebo (Caramel in sterile water)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Phase III Randomized Trial to Compare Standard Therapy (Erythrocyte Transfusions) With Alternative Therapy (Hydroxyurea) for the Maintenance of Lowered TCD Velocities in Pediatric Subjects With Sickle Cell Anemia and Abnormal Pre-treatment TCD Velocities
Brief Summary: The primary goal of the Phase III TWiTCH trial is to compare 24 months of alternative therapy (hydroxyurea) to standard therapy (transfusions) for pediatric subjects with sickle cell anemia and abnormally high (≥200 cm/sec) Transcranial Doppler (TCD) velocities, who currently receive chronic transfusions to reduce the risk of primary stroke. For the alternative treatment regimen (hydroxyurea) to be declared non-inferior to the standard treatment regimen (transfusions), after adjusting for baseline differences, the hydroxyurea-treated group must have a mean TCD velocity similar to that observed with transfusion prophylaxis.


Options:
A: Arm Label: Longitudinal Portion; Type: EXPERIMENTAL; Interventions: Procedure: TCD examination | Arm Label: Treatment Phase; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea, Procedure: TCD examination | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Treatment Phase | Intervention Type: PROCEDURE; Name: TCD examination; Assigned to Arm(s): Longitudinal Portion, Treatment Phase
B: Arm Label: Stem Cell Transplantation; Type: EXPERIMENTAL; Interventions: Procedure: Stem cell transplantation | Arm Label: Transfusion program; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transfusion program | Intervention Type: PROCEDURE; Name: Stem cell transplantation; Assigned to Arm(s): Stem Cell Transplantation | Intervention Type: PROCEDURE; Name: Transfusion program; Assigned to Arm(s): Transfusion program
C: Arm Label: Hydroxyurea Treatment; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea Treatment
D: Arm Label: Standard Therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Treatment Arm

Answer: D